A Study of the Experimental Medicine F901318 for Invasive Fungal Infections in Patients Lacking Treatment Options

Open to people ages 16 years and up

• Male and female aged at least 18 years, or male and female aged 16 years or 17 years and who weigh at least 40 kg whom have given informed consent
• Ability and willingness to comply with the protocol.
• Able to take oral medication
• Females must be non-lactating and at no risk of pregnancy
• Male with female partners of childbearing potential must either abstain from sexual intercourse or use a highly effective means of contraception
• Participants with invasive fungal disease
• Participants who have limited alternative treatment options

• Women who are pregnant or breastfeeding.
• Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug.
• Participants with chronic aspergillosis, aspergilloma or allergic bronchopulmonary aspergillosis.
• Human Immunodeficiency Virus (HIV) infection but not currently receiving antiretroviral therapy.
• Participants with a medical condition that may jeopardize adherence to the protocol or may cause unacceptable additional risk to the participant
• Previously enrolled participants or participants enrolled in any clinical trial within the last 30 days
• Participants receiving treatment limited to supportive care due to predicted short survival time.
• Prohibited concomitant medications.
• Any exclusion criteria required by local regulatory authorities.